Top

Clinical Reviews in Allergy & Immunology

Published in:

01-08-2010

Autoreactive B Cells and Epigenetics

Authors: Yves Renaudineau, Soizic Garaud, Christelle Le Dantec, Ruby Alonso-Ramirez, Capucine Daridon, Pierre Youinou

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2010

Abstract

Autoreactive B cells are central in the pathogenesis of autoimmune diseases (AID) not only by producing autoantibodies but also by secreting cytokines and by presenting autoantigens. Changes in DNA methylation, histone modifications, and miRNA expression, the hallmarks of epigenetic failure, characterize B cells isolated from patients with AID, highlighting the contribution of epigenetic processes to autoreactivity. Additional evidence of epigenetic involvement in the development of B cell autoreactivity comes from in vivo and in vitro studies using DNA demethylating agents as accelerating factors or histone deacetylase inhibitors as repressing factors. As a result, a better understanding of the altered epigenetic processes in AID and in particular in B cells opens perspectives for the development of new therapeutics.

Hom G, Graham RR, Modrek B et al (2008) Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 358:900–909CrossRefPubMed

Fraga MF, Ballestar E, Paz MF et al (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 102:10604–10609CrossRefPubMed

Garaud S, Le Dantec C, Jousse-Joulin S et al (2009) IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J Immunol 182:5623–5632CrossRefPubMed

Balada E, Ordi-Ros J, Vilardell-Tarrés M (2007) DNA methylation and systemic lupus erythematosus. Ann N Y Acad Sci 1108:127–136CrossRefPubMed

Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M (1990) Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33:1665–1673CrossRefPubMed

Neidhart M, Rethage J, Kuchen S et al (2000) Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum 43:2634–2647CrossRefPubMed

Lee YH, Rho YH, Choi SJ, Ji JD, Song GG (2007) PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int 27:827–833CrossRefPubMed

Webb R, Wren JD, Jeffries M et al (2009) Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum 60:1076–1084CrossRefPubMed

Sawalha AH, Webb R, Han S et al (2008) Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS ONE 3:e1727CrossRefPubMed

10.

Chen CZ, Li L, Lodish HF, Bartel DP (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303:83–86CrossRefPubMed

11.

Lindsay MA (2008) MicroRNAs and the immune response. Trends Immunol 29:343–351CrossRefPubMed

12.

Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK (2008) Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10:R101CrossRefPubMed

13.

Nakasa T, Miyaki S, Okubo A et al (2008) Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 58:1284–1292CrossRefPubMed

14.

Tang Y, Luo X, Cui H et al (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60:1065–1075CrossRefPubMed

15.

Dai Y, Huang YS, Tang M et al (2007) Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 16:939–946CrossRefPubMed

16.

Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y (2008) Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int . doi:10.1007/s00296-008-0758-6

17.

Danbara M, Kameyama K, Higashihara M, Takagaki Y (2002) DNA methylation dominates transcriptional silencing of Pax5 in terminally differentiated B cell lines. Mol Immunol 38:1161–1166CrossRefPubMed

18.

Amaravadi L, Klemsz MJ (1999) DNA methylation and chromatin structure regulate PU.1 expression. DNA Cell Biol 18:875–884CrossRefPubMed

19.

Maier H, Colbert J, Fitzsimmons D, Clark DR, Hagman J (2003) Activation of the early B-cell-specific mb-1 (Ig-alpha) gene by Pax-5 is dependent on an unmethylated Ets binding site. Mol Cell Biol 23:1946–1960CrossRefPubMed

20.

Walter K, Bonifer C, Tagoh H (2008) Stem cell-specific epigenetic priming and B cell-specific transcriptional activation at the mouse Cd19 locus. Blood 112:1673–1682CrossRefPubMed

21.

Schwab J, Illges H (2001) Silencing of CD21 expression in synovial lymphocytes is independent of methylation of the CD21 promoter CpG island. Rheumatol Int 20:133–137CrossRefPubMed

22.

O’Carroll D, Mecklenbrauker I, Das PP et al (2007) A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev 21:1999–2004CrossRefPubMed

23.

Koralov SB, Muljo SA, Galler GR et al (2008) Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 132:860–874CrossRefPubMed

24.

Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD (2008) MicroRNAs: new regulators of immune cell development and function. Nat Immunol 9:839–845CrossRefPubMed

25.

Thai TH, Calado DP, Casola S et al (2007) Regulation of the germinal center response by microRNA-155. Science 316:604–608CrossRefPubMed

26.

Rodriguez A, Vigorito E, Clare S et al (2007) Requirement of bic/microRNA-155 for normal immune function. Science 316:608–611CrossRefPubMed

27.

Xiao C, Calado DP, Galler G et al (2007) MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131:146–159CrossRefPubMed

28.

Baxter J, Sauer S, Peters A et al (2004) Histone hypomethylation is an indicator of epigenetic plasticity in quiescent lymphocytes. EMBO J 23:4462–4472CrossRefPubMed

29.

Estève PO, Chin HG, Smallwood A et al (2006) Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 20:3089–3103CrossRefPubMed

30.

Thomas LR, Miyashita H, Cobb RM et al (2008) Functional analysis of histone methyltransferase g9a in B and T lymphocytes. J Immunol 181:485–493PubMed

31.

Ehrlich M, Jackson K, Weemaes C (2006) Immunodeficiency, centromeric region instability, facial anomalies syndrome (ICF). Orphanet J Rare Dis 1:2CrossRefPubMed

32.

Blanco-Betancourt CE, Moncla A, Milili M et al (2004) Defective B-cell-negative selection and terminal differentiation in the ICF syndrome. Blood 103:2683–2690CrossRefPubMed

33.

Jin B, Tao Q, Peng J et al (2008) DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Hum Mol Genet 17:690–709CrossRefPubMed

34.

Ehrlich M, Sanchez C, Shao C et al (2008) ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. Autoimmunity 41:253–271CrossRefPubMed

35.

Lee SC, Bottaro A, Insel RA (2003) Activation of terminal B cell differentiation by inhibition of histone deacetylation. Mol Immunol 39:923–932CrossRefPubMed

36.

Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K (2000) Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol Cell Biol 20:2592–2603CrossRefPubMed

37.

Ancelin K, Lange UC, Hajkova P et al (2006) Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat Cell Biol 8:623–630CrossRefPubMed

38.

Gyory I, Wu J, Fejér G, Seto E, Wright KL (2004) PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol 5:299–308CrossRefPubMed

39.

Xu CR, Feeney AJ (2009) The epigenetic profile of Ig genes is dynamically regulated during B cell differentiation and is modulated by pre-B cell receptor signaling. J Immunol 182:1362–1369CrossRefPubMed

40.

Espinoza CR, Feeney AJ (2007) Chromatin accessibility and epigenetic modifications differ between frequently and infrequently rearranging VH genes. Mol Immunol 44:2675–2685CrossRefPubMed

41.

Nakase H, Takahama Y, Akamatsu Y (2003) Effect of CpG methylation on RAG1/RAG2 reactivity: implications of direct and indirect mechanisms for controlling V(D)J cleavage. EMBO 4:774–780CrossRef

42.

Larijani M, Frieder D, Sonbuchner TM et al (2005) Methylation protects cytidines from AID-mediated deamination. Mol Immunol 42:599–604CrossRefPubMed

43.

Odegard VH, Kim ST, Anderson SM, Shlomchik MJ, Schatz DG (2005) Histone modifications associated with somatic hypermutation. Immunity 23:101–110CrossRefPubMed

44.

Youinou P, Taher TE, Pers JO, Mageed RA, Renaudineau Y (2009) B-lymphocyte cytokines and rheumatic autoimmune disease. Arthritis Rheum 60:1873–1880CrossRefPubMed

45.

Harris DP, Haynes L, Sayles PC et al (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1:475–482CrossRefPubMed

46.

Pang Y, Norihisa Y, Benjamin D, Kantor RR, Young HA (1992) Interferon-gamma gene expression in human B-cell lines: induction by interleukin-2, protein kinase C activators, and possible effect of hypomethylation on gene regulation. Blood 80:724–732PubMed

47.

Janson PC, Marits P, Thörn M, Ohlsson R, Winqvist O (2008) CpG methylation of the IFNG gene as a mechanism to induce immunosuppression [correction of immunosupression] in tumor-infiltrating lymphocytes. J Immunol 181:2878–2886PubMed

48.

Yamamoto I, Matsunaga T, Sakata K, Nakamura Y, Doi S, Hanmyou F (1996) Histone hyperacetylation plays a role in augmentation of IL-4-induced IgE production in LPS-stimulated murine B-lymphocytes by sodium butyrate. J Biochem 119:1056–1061PubMed

49.

Cannat A, Seligmann M (1968) Induction by isoniazid and hydrallazine of antinuclear factors in mice. Clin Exp Immunol 3:99–105PubMed

50.

Ten Veen JH, Feltkamp TE (1972) Studies on drug induced lupus erythematosus in mice. I. Drug induced antinuclear antibodies (ANA). Clin Exp Immunol 11:265–276PubMed

51.

Dubroff LM, Reid RJ Jr (1980) Hydralazine-pyrimidine interactions may explain hydralazine-induced lupus erythematosus. Sciences 208:404–406

52.

Lee BH, Yegnasubramanian S, Lin X, Nelson WG (2005) Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 280:40749–40756CrossRefPubMed

53.

Deng C, Lu Q, Zhang Z et al (2003) Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 48:746–756CrossRefPubMed

54.

Quddus J, Johnson KJ, Gavalchin J et al (1993) Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 92:38–53CrossRefPubMed

55.

Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC (1995) Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154:3025–3035PubMed

56.

Mazari L, Ouarzane M, Zouali M (2007) Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus. Proc Natl Acad Sci U S A 104:6317–6322CrossRefPubMed

57.

Bauer VW, Squire TL, Lowe ME, Andrews MT (2001) Expression of a chimeric retroviral-lipase mRNA confers enhanced lipolysis in a hibernating mammal. Am J Physiol Regul Integr Comp Physiol 281:R1186–R1192PubMed

58.

Wu J, Zhou T, He J, Mountz JD (1993) Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 178:461–468CrossRefPubMed

59.

Qian Y, Santiago C, Borrero M, Tedder TF, Clarke SH (2001) Lupus-specific antiribonucleoprotein B cell tolerance in nonautoimmune mice is maintained by differentiation to B-1 and governed by B cell receptor signaling thresholds. J Immunol 166:2412–2419PubMed

60.

Hippen KL, Tze LE, Behrens TW (2000) CD5 maintains tolerance in anergic B cells. J Exp Med 191:883–890CrossRefPubMed

61.

Jamin C, Magadur G, Lamour A et al (1992) Cell-free CD5 in patients with rheumatic diseases. Immunol Lett 31:79–83CrossRefPubMed

62.

Lu X, Axtell RC, Collawn JF, Gibson A, Justement LB, Raman C (2002) AP2 adaptor complex-dependent internalization of CD5: differential regulation in T and B cells. J Immunol 168:5612–5620PubMed

63.

Renaudineau Y, Hillion S, Saraux A, Mageed RA, Youinou P (2005) An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes. Blood 106:2781–2789CrossRefPubMed

64.

Garaud S, Le Dantec C, Berthou C, Lydyard PM, Youinou P, Renaudineau Y (2008) Selection of the alternative exon 1 from the cd5 gene down-regulates membrane level of the protein in B lymphocytes. J Immunol 181:2010–2018PubMed

65.

Renaudineau Y, Vallet S, Le Dantec C, Hillion S, Saraux A, Youinou P (2005) Characterization of the human CD5 endogenous retrovirus-E in B lymphocytes. Genes Immun 6:663–671PubMed

66.

Pullmann R Jr, Bonilla E, Phillips PE, Middleton FA, Perl A (2008) Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum 58:532–540CrossRefPubMed

67.

Perl A, Colombo E, Dai H et al (1995) Antibody reactivity to the HRES-1 endogenous retroviral element identifies a subset of patients with systemic lupus erythematosus and overlap syndromes. Correlation with antinuclear antibodies and HLA class II alleles. Arthritis Rheum 38:1660–1671CrossRefPubMed

68.

Nagy G, Ward J, Mosser DD et al (2006) Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. J Biol Chem 281:34574–34591CrossRefPubMed

69.

Fernandez DR, Telarico T, Bonilla E et al (2009) Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol 182:2063–2073CrossRefPubMed

70.

Adelman MK, Marchalonis JJ (2002) Endogenous retroviruses in systemic lupus erythematosus: candidate lupus viruses. Clin Immunol 102:107–116CrossRefPubMed

71.

Chambers AE, Banerjee S, Chaplin T et al (2003) Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 39:1165–1175CrossRefPubMed

72.

Zabel MD, Weis JJ, Weis JH (1999) Lymphoid transcription of the murine CD21 gene is positively regulated by histone acetylation. J Immunol 163:2697–2703PubMed

73.

Seo JS, Cho NY, Kim HR et al (2008) Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A. Oncol Rep 19:93–98PubMed

74.

Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111:539–552PubMed

75.

Xiao C, Srinivasan L, Calado DP et al (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17–92 expression in lymphocytes. Nat Immunol 9:405–414CrossRefPubMed

76.

Park BL, Kim LH, Shin HD, Park YW, Uhm WS, Bae SC (2004) Association analyses of DNA methyltransferase-1 (DNMT1) polymorphisms with systemic lupus erythematosus. J Hum Genet 49:642–646CrossRefPubMed

77.

Gorelik G, Fang JY, Wu A, Sawalha AH, Richardson B (2007) Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol 179:5553–5563PubMed

78.

Miyamoto A, Nakayama K, Imaki H et al (2002) Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. Nature 416:865–869CrossRefPubMed

79.

Jury EC, Isenberg DA, Mauri C, Ehrenstein MR (2006) Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 177:7416–7422PubMed

80.

Oelke K, Lu Q, Richardson D et al (2004) Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum 50:1850–1860CrossRefPubMed

81.

Nagumo H, Agematsu K (1998) Synergistic augmentative effect of interleukin-10 and CD27/CD70 interactions on B-cell immunoglobulin synthesis. Immunology 94:388–394CrossRefPubMed

82.

Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY (2006) Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119:296–305CrossRefPubMed

83.

Tang LP, Cho CH, Hui WM et al (2006) An inverse correlation between Interleukin-6 and select gene promoter methylation in patients with gastric cancer. Digestion 74:85–90CrossRefPubMed

84.

Hillion S, Garaud S, Devauchelle V et al (2007) Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus. Immunology 122:371–380CrossRefPubMed

85.

Hu N, Qiu X, Luo Y et al (2008) Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol 35:804–810PubMed

86.

Lei W, Luo Y, Yan K et al (2009) Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol 14:1–6

87.

Huber LC, Brock M, Hemmatazad H et al (2007) Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 56:1087–1093CrossRefPubMed

Title: Autoreactive B Cells and Epigenetics
Authors: Yves Renaudineau
Soizic Garaud
Christelle Le Dantec
Ruby Alonso-Ramirez
Capucine Daridon
Pierre Youinou
Publication date: 01-08-2010
Publisher: Humana Press Inc
Published in: Clinical Reviews in Allergy & Immunology / Issue 1/2010
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-009-8174-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Epigenetic Histone Code and Autoimmunity

The Revolution of Epigenetics in the Field of Autoimmunity

The Human Endogenous Retrovirus Link between Genes and Environment in Multiple Sclerosis and in Multifactorial Diseases Associating Neuroinflammation

Epigenetic Perspectives in Systemic Lupus Erythematosus: Pathogenesis, Biomarkers, and Therapeutic Potentials

The Role of Epigenetics in Aging and Autoimmunity

Epigenetics in Rheumatoid Arthritis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials